Research Article

Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study

Table 4

Multivariate analyses of prognostic factors for progression-free survival in first-line sorafenib-treated patients ().

ParameterUnivariate analysis of PFSMultivariate analysis of PFS
Hazard ratio valueConfidence intervalHazard ratio valueConfidence interval

Gender, female0.560.0660.30–1.04
Age ≥65 years1.040.8590.66–1.66
KPS <80%1.870.0620.97–3.61
LDH >1.5x ULN0.700.6250.17–2.90
Hemoglobin <LLN1.780.0191.10–2.870.410.2200.10–1.70
cCa >10 mg/dL0.830.6840.33–2.06
Time from diagnosis to treatment <1 year2.880.0001.72–4.811.900.2420.65–5.59
Leukocytosis2.350.0321.08–5.132.410.2740.50–11.61
Thrombocytosis4.060.0011.78–9.300.830.8750.09–8.02
Hypoalbuminemia1.930.0890.91–4.10
Prior nephrectomy1.980.4990.27–14.33
Prior metastasectomy0.890.6830.52–1.53
Brain metastasis1.040.8670.63–1.73
Bone metastasis1.650.0660.97–2.81
Liver metastasis2.160.0580.98–4.80
Lung metastasis0.720.1870.44–1.17
Lymph node metastasis1.820.0401.03–3.231.980.3650.45–8.72
Pancreas1.160.7080.53–2.56
Contralateral kidney0.230.1490.03–1.69
Metastatic sites
 11.001.00
 2-31.280.3200.78–2.100.800.7830.17–3.80
 43.960.0121.35–11.5628.570.0191.74–468.69
T stage
 T1-21.001.00
 T3-41.970.0081.19–3.264.340.0251.20–15.71
 N12.660.0011.51–4.680.750.8370.05–11.95
 M12.080.0441.02–4.220.750.6740.20–2.86
Fuhrman grade
 1-21.00
 3-40.980.9550.57–1.71
Primary tumor size
 <4 cm1.00
 4–7 cm0.870.7370.37–2.000.370.2880.06–2.30
 >7 cm0.850.6900.39–1.860.310.1860.05–1.76
Collecting system invasion2.110.0261.09–4.070.070.0120.01–0.55
Capsule invasion1.050.8690.59–1.88
Lymphovascular invasion2.410.0041.33–4.3713.350.0091.91–93.37
Tumor necrosis2.010.0221.10–3.656.690.0022.06–21.73

KPS, Karnofsky performance status; LDH, lactate dehydrogenase; ULN, upper limit normal; LLN, lower limit normal; cCa, corrected calcium.